Studies on NSCLC have shown that patients with high expression of PD-L1 on the surface of tumor cells have significantly better clinical responses to PD-1/PD-L1 inhibitors (Passiglia et al., 2016; Muller et al., 2017). The gene discussed is PDCD1; the disease is neoplasm.